Skip to main content
Top
Published in: Acta Diabetologica 5/2012

01-10-2012 | Original Article

Assessment of HbA1c as a diagnostic tool in diabetes and prediabetes

Authors: Tsvetalina Tankova, Nevena Chakarova, Lilia Dakovska, Iliana Atanassova

Published in: Acta Diabetologica | Issue 5/2012

Login to get access

Abstract

To evaluate HbA1c as a diagnostic tool in prediabetes—impaired fasting glucose (IFG) and impaired glucose tolerance (IGT), and newly detected diabetes (NDD), defined by plasma glucose and OGTT. 2,231 subjects, of mean age 50.3 ± 13.9 years and mean BMI 29.5 ± 6.2 kg/m2, underwent an OGTT. HbA1c performance was assessed using the area under the receiver operating characteristics curve (AUC-ROC). HbA1c was significantly higher in all groups with altered glucose tolerance—5.72 ± 0.61% in IFG, 5.84 ± 0.63% in IGT, and 7.5 ± 1.69% in NDD when compared to normal glucose tolerance—5.23 ± 0.65% (P < 0.0001). HbA1c of both prediabetic groups was significantly lower in comparison with NDD (P < 0.0001); in IGT being significantly higher than in IFG (P = 0.02). ROC analysis demonstrated good performance of HbA1c for diagnosing diabetes—AUC-ROC 0.958 (95% CI: 0.946–0.970), as well as prediabetes—AUC-ROC 0.729 (95% CI: 0.702–0.755). The optimal cut-off level of HbA1c for diagnosing diabetes was 6.1% (sensitivity 86%, specificity 92%) and for undiagnosed prediabetes—5.5% (sensitivity 71%, specificity 64%). HbA1c appears to be a useful, convenient, and reliable tool for identifying subjects with prediabetes and diabetes and should be considered in the development of diagnostic strategies.
Literature
1.
go back to reference International Diabetes Federation (2009) IDF diabetes atlas, 4th edn. International Diabetes Federation, Brussels International Diabetes Federation (2009) IDF diabetes atlas, 4th edn. International Diabetes Federation, Brussels
2.
go back to reference Harris MI (1993) Undiagnosed NIDDM: clinical and public health issues. Diabetes Care 16:642–652PubMed Harris MI (1993) Undiagnosed NIDDM: clinical and public health issues. Diabetes Care 16:642–652PubMed
3.
go back to reference Harris MI, Klein R, Welborn T, Knuiman MW (1992) Onset of NIDDM occurs at least 4–7 yr before clinical diagnosis. Diabetes Care 15:815–819PubMedCrossRef Harris MI, Klein R, Welborn T, Knuiman MW (1992) Onset of NIDDM occurs at least 4–7 yr before clinical diagnosis. Diabetes Care 15:815–819PubMedCrossRef
4.
go back to reference Barr EL, Zimmet PZ, Welborn TA, Jolley D, Magliano DJ, Dunstan DW et al (2007) Risk of cardiovascular and all-cause mortality in individuals with diabetes mellitus, impaired fasting glucose and impaired glucose tolerance. The Australian diabetes, obesity and lifestyle study (AusDiab). Circulation 116:1–7CrossRef Barr EL, Zimmet PZ, Welborn TA, Jolley D, Magliano DJ, Dunstan DW et al (2007) Risk of cardiovascular and all-cause mortality in individuals with diabetes mellitus, impaired fasting glucose and impaired glucose tolerance. The Australian diabetes, obesity and lifestyle study (AusDiab). Circulation 116:1–7CrossRef
5.
go back to reference Diabetes Prevention Program Research Group (2007) The prevalence of retinopathy in impaired glucose tolerance and recent-onset diabetes in the diabetes prevention program. Diabet Med 24:137–144CrossRef Diabetes Prevention Program Research Group (2007) The prevalence of retinopathy in impaired glucose tolerance and recent-onset diabetes in the diabetes prevention program. Diabet Med 24:137–144CrossRef
6.
go back to reference Nguyen TT, Wang JJ, Wong TY (2007) Retinal vascular changes in prediabetes and prehypertension: new findings and their research and clinical implications. Diabetes Care 30:2708–2715PubMedCrossRef Nguyen TT, Wang JJ, Wong TY (2007) Retinal vascular changes in prediabetes and prehypertension: new findings and their research and clinical implications. Diabetes Care 30:2708–2715PubMedCrossRef
7.
go back to reference Sumner CJ, Sheth S, Griffin JW, Cornblath DR, Polydefkis M (2003) The spectrum of neuropathy in diabetes and impaired glucose tolerance. Neurology 60(1):108–111PubMedCrossRef Sumner CJ, Sheth S, Griffin JW, Cornblath DR, Polydefkis M (2003) The spectrum of neuropathy in diabetes and impaired glucose tolerance. Neurology 60(1):108–111PubMedCrossRef
8.
go back to reference World Health Organization (2006) Definition and diagnosis of diabetes mellitus and intermediate hyperglycemia. Report of a WHO/IDF consultation. WHO, Geneva World Health Organization (2006) Definition and diagnosis of diabetes mellitus and intermediate hyperglycemia. Report of a WHO/IDF consultation. WHO, Geneva
9.
go back to reference Saudek CD, Herman WH, Sacks DB, Bergenstal RM, Edelman D, Davidson MB (2008) A new look at screening and diagnosing diabetes mellitus. J Clin Endocrinol 93(7):2447–2453CrossRef Saudek CD, Herman WH, Sacks DB, Bergenstal RM, Edelman D, Davidson MB (2008) A new look at screening and diagnosing diabetes mellitus. J Clin Endocrinol 93(7):2447–2453CrossRef
10.
go back to reference Stern MP, Williams K, Haffner SM (2002) Identification of persons at high risk for type 2 diabetes mellitus: do we need the oral glucose tolerance test? Ann Intern Med 136:575–581PubMed Stern MP, Williams K, Haffner SM (2002) Identification of persons at high risk for type 2 diabetes mellitus: do we need the oral glucose tolerance test? Ann Intern Med 136:575–581PubMed
11.
go back to reference Tamborlane WV, Kollman C, Steffes MW, Ruedy KJ, Dongyuan X, Beck RW et al (2005) Diabetes Research in Children Network (DirecNet) Study Group. Comparison of fingerstick hemoglobin A1c levels assayed by DCA 2000 with the DCCT/EDIC central laboratory assay: results of a diabetes research in children network (DirecNet) study. Pediatr Diabetes 6(1):13–16PubMedCrossRef Tamborlane WV, Kollman C, Steffes MW, Ruedy KJ, Dongyuan X, Beck RW et al (2005) Diabetes Research in Children Network (DirecNet) Study Group. Comparison of fingerstick hemoglobin A1c levels assayed by DCA 2000 with the DCCT/EDIC central laboratory assay: results of a diabetes research in children network (DirecNet) study. Pediatr Diabetes 6(1):13–16PubMedCrossRef
12.
go back to reference Kilpatrick ES, Winocour PH, On behalf of the Association of British Clinical Diabetologists (ABCD) (2010) ABCD position statement on haemoglobin A1c for the diagnosis of diabetes. Pract Diab Int 27(7):306–310CrossRef Kilpatrick ES, Winocour PH, On behalf of the Association of British Clinical Diabetologists (ABCD) (2010) ABCD position statement on haemoglobin A1c for the diagnosis of diabetes. Pract Diab Int 27(7):306–310CrossRef
13.
go back to reference Lapolla A, Dalfrà MG, Fedele D (2010) Pregnancy complicated by diabetes: what is the best level of HbA1c for conception? Acta Diabetol 47(3):187–192PubMedCrossRef Lapolla A, Dalfrà MG, Fedele D (2010) Pregnancy complicated by diabetes: what is the best level of HbA1c for conception? Acta Diabetol 47(3):187–192PubMedCrossRef
14.
go back to reference American Diabetes Association (2010) Standards of medical care in diabetes—2010. Diabetes Care 33(Suppl 1):S4–S10 American Diabetes Association (2010) Standards of medical care in diabetes—2010. Diabetes Care 33(Suppl 1):S4–S10
15.
go back to reference American Diabetes Association (2011) Standards of medical care in diabetes—2011. Diabetes Care 34(Suppl 1):S11–S61CrossRef American Diabetes Association (2011) Standards of medical care in diabetes—2011. Diabetes Care 34(Suppl 1):S11–S61CrossRef
16.
go back to reference Saudek CD, Derr RL, Kalyani RR (2006) Assessing glycemia in diabetes using self-monitoring blood glucose and hemoglobin A1c. JAMA 295:1688–1697PubMedCrossRef Saudek CD, Derr RL, Kalyani RR (2006) Assessing glycemia in diabetes using self-monitoring blood glucose and hemoglobin A1c. JAMA 295:1688–1697PubMedCrossRef
17.
go back to reference Ollerton RL, Playle R, Ahmed K, Dunstan FD, Luzio SD, Owens DR (1999) Day-to-day variability of fasting plasma glucose in newly diagnosed type 2 diabetic subjects. Diabetes Care 22(3):394–398PubMedCrossRef Ollerton RL, Playle R, Ahmed K, Dunstan FD, Luzio SD, Owens DR (1999) Day-to-day variability of fasting plasma glucose in newly diagnosed type 2 diabetic subjects. Diabetes Care 22(3):394–398PubMedCrossRef
18.
go back to reference Petersen PH, Jørgensen LG, Brandslund I, De Fine Olivarius N, Stahl M (2005) Consequences of bias and imprecision in measurements of glucose and HbA1c for the diagnosis and prognosis of diabetes mellitus. Scand J Clin Lab Invest 240:51–60CrossRef Petersen PH, Jørgensen LG, Brandslund I, De Fine Olivarius N, Stahl M (2005) Consequences of bias and imprecision in measurements of glucose and HbA1c for the diagnosis and prognosis of diabetes mellitus. Scand J Clin Lab Invest 240:51–60CrossRef
19.
go back to reference Sacks DB, Bruns DE, Goldstein DE, Maclaren NK, McDonald JM, Parrott M (2002) Guidelines and recommendations for laboratory analysis in the diagnosis and management of diabetes mellitus. Clin Chem 48(3):436–472PubMed Sacks DB, Bruns DE, Goldstein DE, Maclaren NK, McDonald JM, Parrott M (2002) Guidelines and recommendations for laboratory analysis in the diagnosis and management of diabetes mellitus. Clin Chem 48(3):436–472PubMed
20.
go back to reference Selvin E, Crainiceanu CM, Brancati FL, Coresh J (2007) Short-term variability in measures of glycemia and implications for the classification of diabetes. Arch Intern Med 167(14):1545PubMedCrossRef Selvin E, Crainiceanu CM, Brancati FL, Coresh J (2007) Short-term variability in measures of glycemia and implications for the classification of diabetes. Arch Intern Med 167(14):1545PubMedCrossRef
21.
go back to reference Consensus Committee (2007) Consensus statement on the worldwide standardization of the hemoglobin A1C measurement: The American Diabetes Association, European Association for the Study of Diabetes, International Federation of Clinical Chemistry and laboratory medicine, and the International Diabetes Federation. Diabetes Care 30:2399–2400CrossRef Consensus Committee (2007) Consensus statement on the worldwide standardization of the hemoglobin A1C measurement: The American Diabetes Association, European Association for the Study of Diabetes, International Federation of Clinical Chemistry and laboratory medicine, and the International Diabetes Federation. Diabetes Care 30:2399–2400CrossRef
22.
go back to reference Little RR (2003) Glycated hemoglobin standardization—National Glycohemoglobin Standardization Program (NGSP) perspective. Clin Chem Lab 41:1191–1198 Little RR (2003) Glycated hemoglobin standardization—National Glycohemoglobin Standardization Program (NGSP) perspective. Clin Chem Lab 41:1191–1198
23.
go back to reference Sacks DB (2005) ADA/EASD/IDF Working Group of the HbA1c Assay. Global harmonization of hemoglobin A1c. Clin Chem 51:681–683PubMedCrossRef Sacks DB (2005) ADA/EASD/IDF Working Group of the HbA1c Assay. Global harmonization of hemoglobin A1c. Clin Chem 51:681–683PubMedCrossRef
24.
go back to reference International Expert Committee (2009) International expert committee report on the role of the A1C assay in the diagnosis of diabetes. Diabetes Care 32:1327–1334CrossRef International Expert Committee (2009) International expert committee report on the role of the A1C assay in the diagnosis of diabetes. Diabetes Care 32:1327–1334CrossRef
25.
go back to reference American Diabetes Association (2010) Diagnosis and classification of diabetes mellitus. Diabetes Care 33(Suppl 1):S62–S69CrossRef American Diabetes Association (2010) Diagnosis and classification of diabetes mellitus. Diabetes Care 33(Suppl 1):S62–S69CrossRef
26.
go back to reference American Diabetes Association (2011) Diagnosis and classification of diabetes mellitus. Diabetes Care 34(Suppl 1):S62–S69CrossRef American Diabetes Association (2011) Diagnosis and classification of diabetes mellitus. Diabetes Care 34(Suppl 1):S62–S69CrossRef
28.
go back to reference Expert Committee on the Diagnosis, Classification of Diabetes Mellitus (1997) Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care 20:1183–1197 Expert Committee on the Diagnosis, Classification of Diabetes Mellitus (1997) Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care 20:1183–1197
29.
go back to reference Davidson MB, Schriger DL, Peters AL, Lorber B (1999) Relationship between fasting plasma glucose and glycosylated hemoglobin: potential for false-positive diagnoses of type 2 diabetes using new diagnostic criteria. JAMA 281(13):1203–1210PubMedCrossRef Davidson MB, Schriger DL, Peters AL, Lorber B (1999) Relationship between fasting plasma glucose and glycosylated hemoglobin: potential for false-positive diagnoses of type 2 diabetes using new diagnostic criteria. JAMA 281(13):1203–1210PubMedCrossRef
30.
go back to reference (1995) The relationship of glycemic exposure (HbA1c) to the risk of development and progression of retinopathy in the diabetes control and complications trial. Diabetes 44(8):968–983 (1995) The relationship of glycemic exposure (HbA1c) to the risk of development and progression of retinopathy in the diabetes control and complications trial. Diabetes 44(8):968–983
31.
go back to reference AACE/ACE (2010) A1C position statement. Endocr Pract 16(2):155–156 AACE/ACE (2010) A1C position statement. Endocr Pract 16(2):155–156
32.
go back to reference Lindstrom J, Tuomilehto J (2003) The diabetes risk score: a practical tool to predict type 2 diabetes risk. Diabetes Care 26:725–731PubMedCrossRef Lindstrom J, Tuomilehto J (2003) The diabetes risk score: a practical tool to predict type 2 diabetes risk. Diabetes Care 26:725–731PubMedCrossRef
33.
go back to reference World Health Organization (1999) Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus. Report of a WHO consultation. WHO, Geneva World Health Organization (1999) Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus. Report of a WHO consultation. WHO, Geneva
34.
go back to reference Nakagami T, Qiao Q, Tuomilehto J, Balkau B, Tajima N, Hu G et al (2006) Screen-detected diabetes, hypertension and hypercholesterolemia as predictors of cardiovascular mortality in five populations of Asian origin: the DECODA study. Eur J Cardiovasc Prev Rehabil 13(4):555–561PubMedCrossRef Nakagami T, Qiao Q, Tuomilehto J, Balkau B, Tajima N, Hu G et al (2006) Screen-detected diabetes, hypertension and hypercholesterolemia as predictors of cardiovascular mortality in five populations of Asian origin: the DECODA study. Eur J Cardiovasc Prev Rehabil 13(4):555–561PubMedCrossRef
35.
go back to reference Spijkerman AM, Adriaanse MC, Dekker JM, Nijpels G, Stehouwer CD, Bouter LM et al (2002) Diabetic patients detected by population-based stepwise screening already have a diabetic cardiovascular risk profile. Diabetes Care 25:1784–1789PubMedCrossRef Spijkerman AM, Adriaanse MC, Dekker JM, Nijpels G, Stehouwer CD, Bouter LM et al (2002) Diabetic patients detected by population-based stepwise screening already have a diabetic cardiovascular risk profile. Diabetes Care 25:1784–1789PubMedCrossRef
36.
go back to reference Buell C, Kermah D, Davidson MB (2007) Utility of A1C for diabetes screening in the 1999–2004 NHANES population. Diabetes Care 30:2233–2235PubMedCrossRef Buell C, Kermah D, Davidson MB (2007) Utility of A1C for diabetes screening in the 1999–2004 NHANES population. Diabetes Care 30:2233–2235PubMedCrossRef
37.
go back to reference Rohlfing CL, Wiedmeyer HM, Little RR, England JD, Tennill A, Goldstein DE (2002) Defining the relationship between plasma glucose and HbA(1c): analysis of glucose profiles and HbA(1c) in the diabetes control and complications trial. Diabetes Care 25(2):275–278PubMedCrossRef Rohlfing CL, Wiedmeyer HM, Little RR, England JD, Tennill A, Goldstein DE (2002) Defining the relationship between plasma glucose and HbA(1c): analysis of glucose profiles and HbA(1c) in the diabetes control and complications trial. Diabetes Care 25(2):275–278PubMedCrossRef
38.
go back to reference Ko GT, Chan JC, Yeung VT, Chow CC, Tsang LW, Li JK et al (1998) Combined use of a fasting plasma glucose concentration and HbA1c or fructosamine predicts the likelihood of having diabetes in high-risk subjects. Diabetes Care 21:1221–1225PubMedCrossRef Ko GT, Chan JC, Yeung VT, Chow CC, Tsang LW, Li JK et al (1998) Combined use of a fasting plasma glucose concentration and HbA1c or fructosamine predicts the likelihood of having diabetes in high-risk subjects. Diabetes Care 21:1221–1225PubMedCrossRef
39.
go back to reference Hu Y, Liu W, Chen Y, Zhang M, Wang L, Zhou H et al (2010) Combined use of fasting plasma glucose and glycated hemoglobin A1c in the screening of diabetes and impaired glucose tolerance. Acta Diabetol 47(3):231–236PubMedCrossRef Hu Y, Liu W, Chen Y, Zhang M, Wang L, Zhou H et al (2010) Combined use of fasting plasma glucose and glycated hemoglobin A1c in the screening of diabetes and impaired glucose tolerance. Acta Diabetol 47(3):231–236PubMedCrossRef
40.
go back to reference Mohan V, Vijayachandrika V, Gokulakrishnan K, Anjana RM, Ganesan A, Weber MB et al (2010) A1C cut points to define various glucose intolerance groups in Asian Indians. Diabetes Care 33(3):515–519PubMedCrossRef Mohan V, Vijayachandrika V, Gokulakrishnan K, Anjana RM, Ganesan A, Weber MB et al (2010) A1C cut points to define various glucose intolerance groups in Asian Indians. Diabetes Care 33(3):515–519PubMedCrossRef
41.
go back to reference Droumaguet C, Balkau B, Simon D, Caces E, Tichet J, Charles MA et al (2006) DESIR Study Group. Use of HbA1c in predicting progression to diabetes in french men and women: data from an epidemiological study on the insulin resistance syndrome (DESIR). Diabetes Care 29(7):1619–1625PubMedCrossRef Droumaguet C, Balkau B, Simon D, Caces E, Tichet J, Charles MA et al (2006) DESIR Study Group. Use of HbA1c in predicting progression to diabetes in french men and women: data from an epidemiological study on the insulin resistance syndrome (DESIR). Diabetes Care 29(7):1619–1625PubMedCrossRef
42.
go back to reference Bennett CM, Guo M, Dharmage SC (2007) HbA(1c) as a screening tool for detection of type 2 diabetes: a systematic review. Diabet Med 24:333–343PubMedCrossRef Bennett CM, Guo M, Dharmage SC (2007) HbA(1c) as a screening tool for detection of type 2 diabetes: a systematic review. Diabet Med 24:333–343PubMedCrossRef
43.
go back to reference Inoue K, Matsumoto M, Kobayashi Y (2007) The combination of fasting plasma glucose and glycosylated hemoglobin predicts type 2 diabetes in Japanese workers. Diabetes Res Clin Pract 77:451–458PubMedCrossRef Inoue K, Matsumoto M, Kobayashi Y (2007) The combination of fasting plasma glucose and glycosylated hemoglobin predicts type 2 diabetes in Japanese workers. Diabetes Res Clin Pract 77:451–458PubMedCrossRef
44.
go back to reference Perry RC, Shankar RR, Fineberg N, McGill J, Baron AD, Early Diabetes Intervention Program (EDIP) (2001) HbA1c measurement improves the detection of type 2 diabetes in high-risk individuals with nondiagnostic levels of fasting plasma glucose: the early diabetes intervention program (EDIP). Diabetes Care 24(11):465–471PubMedCrossRef Perry RC, Shankar RR, Fineberg N, McGill J, Baron AD, Early Diabetes Intervention Program (EDIP) (2001) HbA1c measurement improves the detection of type 2 diabetes in high-risk individuals with nondiagnostic levels of fasting plasma glucose: the early diabetes intervention program (EDIP). Diabetes Care 24(11):465–471PubMedCrossRef
45.
go back to reference Zhou X, Pang Z, Gao W, Wang S, Zhang L, Ning F et al (2010) Performance of an A1C and fasting capillary blood glucose test for screening newly diagnosed diabetes and pre-diabetes defined by an oral glucose tolerance test in Qingdao, China. Diabetes Care 33(3):545–550PubMedCrossRef Zhou X, Pang Z, Gao W, Wang S, Zhang L, Ning F et al (2010) Performance of an A1C and fasting capillary blood glucose test for screening newly diagnosed diabetes and pre-diabetes defined by an oral glucose tolerance test in Qingdao, China. Diabetes Care 33(3):545–550PubMedCrossRef
Metadata
Title
Assessment of HbA1c as a diagnostic tool in diabetes and prediabetes
Authors
Tsvetalina Tankova
Nevena Chakarova
Lilia Dakovska
Iliana Atanassova
Publication date
01-10-2012
Publisher
Springer Milan
Published in
Acta Diabetologica / Issue 5/2012
Print ISSN: 0940-5429
Electronic ISSN: 1432-5233
DOI
https://doi.org/10.1007/s00592-011-0334-5

Other articles of this Issue 5/2012

Acta Diabetologica 5/2012 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.